Delivery Order SPE2DE21D0007-SPE2D625F0GUB
- Not listed
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,910.02 on August 6, 2025, for Anti-A Bioclone 15x10ml medical diagnostic reagents. The contract, which will be completed by August 27, 2025, was issued without a set-aside designation, indicating open competition. The funding originates from the Medical Supply Chain within the Department of Defense, with the place of performance located in Raritan, New Jersey. This delivery order...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $1,109.97 to Ortho-Clinical Diagnostics, Inc. for Anti-A Bioclone 15x10ML on August 1, 2025, with an ultimate completion date of August 6, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, indicating open competition. Performance will occur at the contractor's facility in Raritan, New Jersey. Ortho-Clinical Diagnostics, Inc., a for-profit...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on July 11, 2025, by the Medical Supply Chain division of the Department of Defense for the supply of Anti-A Bioclone 15x10ml reagents, valued at $1,156.61. The contract employs fixed-price pricing with economic price adjustment provisions and is scheduled for ultimate completion by August 1, 2025. The work will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was used in this...
- Ortho-Clinical Diagnostics, Inc. was awarded a $1,156.61 fixed-price delivery order by the Defense Medical Supply Chain on July 14, 2025, for the supply of Anti-A Bioclone 15x10ml reagent products. The contract is scheduled for ultimate completion by August 4, 2025, and will be performed at the company's facility in Raritan, New Jersey. No small business set-aside designation was utilized for this award, indicating open competition among qualified vendors. This delivery order represents a...
- Ortho-Clinical Diagnostics, Inc. has been awarded a delivery order contract by the Defense Medical Supply Chain with a ceiling value of $1,767.32 for Rght Anti-A B Bcln 10ml Btl Orth Bb—a specialized blood bank diagnostic reagent. The contract award is dated July 18, 2025, with an ultimate completion date of July 30, 2025, and will be performed at the company's facility in Raritan, New Jersey. This delivery order employs fixed-price contracting with economic price adjustment and was awarded...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on August 8, 2025, for the supply of Anti-A Bioclone 15x10ML reagents, with a ceiling value of $1,832.54. The contract is structured as a fixed-price delivery order with economic price adjustment provisions and is set to complete by August 29, 2025. This award was issued without a set-aside designation, indicating open competition. The place of performance is located in Raritan, New Jersey, which serves as the company's...
- The U.S. Defense Department's Medical Supply Chain agency awarded a delivery order valued at $1,109.97 to Ortho-Clinical Diagnostics, Inc. for Anti-B Bioclone 15x10ML on August 11, 2025, with completion targeted for August 14, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, indicating open competition. Ortho-Clinical Diagnostics, headquartered in Raritan, New Jersey, is a for-profit medical equipment manufacturer specializing...
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,963.68 by the Defense Medical Supply Chain on August 5, 2025, for Rgt Anti-A B Bcln 10mL bottles used in orthopedic blood bank applications. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating open competition, and carries an ultimate completion date of August 8, 2025. Performance will be conducted at the awardee's facility in...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order valued at $1,832.54 by the Defense Department's Medical Supply Chain on August 5, 2025, for the delivery of Ortho Anti-A Blood Clone 150ML Monoclonal ABO Group BB reagent. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating open competition, and is scheduled for ultimate completion by August 8, 2025. Performance will take place at the company's facility in Raritan, New Jersey....
- This is a federal contract award to Ortho-Clinical Diagnostics, Inc., a for-profit medical equipment manufacturer, by the Medical Supply Chain division of the Defense Department's Defense Health Agency. The $1,767.32 firm fixed-price delivery order is for the supply of 4,568,212,039 units of Anti-A,B Bioclone 15x10ml. The contract has a June 2, 2025 completion date and does not utilize a set-aside designation, indicating open competition. Ortho-Clinical Diagnostics, Inc. is a self-certified...
- SPE2DE21D0007Indefinite Delivery Contract
- SPE2DE21D0007-SPE2D625F0GUBDelivery Order
Ortho-Clinical Diagnostics, Inc. was awarded a delivery order on August 6, 2025, by the Defense Medical Supply Chain to supply ANTI-A BioclOne 15x10mL, a diagnostic reagent product. The contract is valued at $1,109.97 under a fixed-price arrangement with economic price adjustment provisions, with an ultimate completion date of August 11, 2025. The work will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was utilized for this award, indicating open competition. This delivery order represents a continuation of Ortho-Clinical Diagnostics' established role as a primary supplier of diagnostic solutions to federal healthcare agencies. The company, headquartered in Raritan and registered as a self-certified HUBZone joint venture, specializes in providing blood bank analyzers, reagents, and laboratory testing infrastructure to agencies including the Department of Veterans Affairs, Indian Health Service, and Defense Health Agency. The award aligns with the company's existing federal portfolio, which includes multiple Indefinite Delivery Vehicles and blanket purchase agreements supporting critical diagnostic capabilities across federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/6/25 |